HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $22 price target.
August 28, 2023 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $22.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Esperion Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100